Back to search results

Special Care Patterns for Elderly Head and Neck Cancer Patients

This study is looking at how different treatments affect older patients (65 and up) with head and neck squamous cell carcinoma (HNSCC), which is a type of cancer in the head or neck. Researchers want to understand if modern radiation treatments like intensity-modulated radiotherapy (IMRT), supportive care, and different ways of giving chemotherapy (like cisplatin weekly) have changed how well elderly patients do. You might be able to join if you're 65 or older, have advanced HNSCC in your mouth, throat, or voice box, and received definitive (chemo-)radiotherapy since 2005. The main goal is to see how long patients live (overall survival) for up to 5 years. The current status of this study is unclear.

Study design
This is an observational study, meaning researchers will look at existing patient information rather than giving new treatments. It plans to include about 1500 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants' overall survival will be measured for up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05337631

Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy

Recruiting
Not specifiedAges 65+Observational
University Hospital Freiburg
~1,500 participants
Updated 2025-03-25 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 18 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall survival (OS)
Measured over Up to 5 years

Conditions

HNSCC
Oral Cavity Cancer
Oropharynx Cancer
Hypopharynx Cancer
Larynx Cancer

Explore related trials

Head and Neck Squamous Cell CarcinomaHypopharyngeal CarcinomaMalignant Laryngeal NeoplasmMalignant Oral NeoplasmOropharyngeal Carcinoma

Where it's being run

18 sites across 7 states
Germany11
Ohio2
Maryland1
New York1
Cyprus1
Czechia1
Switzerland1

Study leadership

  • Nils H. Nicolay, MD, PhD · PRINCIPAL_INVESTIGATOR · Department of Radiation Oncology, Medical Center - University of Freiburg
  • Alexander Rühle, MD · PRINCIPAL_INVESTIGATOR · Department of Radiation Oncology, Medical Center - University of Freiburg

Who to contact

Alexander Rühle, MD, MHBA
[email protected]
004976127095200
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

definitive (chemo-)radiotherapy of locoregionally advanced (cT3-4 and/or cN+) head-and-neck squamous cell carcinomas (HNSCC) of the oral cavity, oropharynx, hypopharynx or larynx
primary treatment since 2005
age ≥65 years at the time of (chemo-)radiotherapy

Exclusion

adjuvant (chemo-)radiotherapy
history of previous head-and-neck cancers or radiotherapy in the head-and-neck region
distant metastases at (chemo-)radiotherapy initiation (cM1)
HNSCCs of the nasopharynx, salivary glands, skin or with unknown primary

What this trial measures

  • Overall survival (OS)Up to 5 years

    Time from radiotherapy start until death from any cause